Veeda Clinical Research’s Laboratory services has added another powerful tool to its bespoke immunochemistry and biomarker services – the Automated “CD” based nanotechnology platform from Gyros called the Gyrolab. This is a high-capacity, low sample and reagent volume system that can improve many immunoassay methods and solve the problems encountered with limited or scarce biological fluid sample volume. It also offers advantages in the amount of antibody required for analytical methods to support drug development projects.

Veeda has a mature laboratory service headed by recognised industry expert John Allinson, who has over 35 years experience in the field of Biomarker analysis, and managed by John Chappell – an immunochemist with 15 years experience in drug development. The group based in Oxford UK, already has a wide range of analytical platforms and scientific knowledge and experience, and have chosen the Gyrolab to add to these and complement the already flexible and comprehensive service offering.

Our Laboratory services are designed to meet the needs of clients requiring immunochemistry assays to support PK, Immunogenicity and Biomarker analysis. We offer a team with an understanding of not only the science but also the client’s expectations in managing what are often complex pieces of a drug development project.

In order to meet these needs, our laboratory services have developed over a number of years to ensure that we have the right mix of staff and equipment to enable us to deliver first class services in this complex field. The inter-disciplinary scientific collaboration we insist upon internally extrapolates to that with our clients, working in close and constant communication throughout the critical phases of technology transfer or development. Clinical & biomedical scientists, physical and immuno-chemists working together to deliver all your analytical requirements.